Anti-Aging & Longevity
Anti-aging peptide research spans from highly speculative Russian bioregulators to emerging mitochondrial medicine (SS-31, MOTS-c, Humanin) with genuine Phase II data. Differentiating marketing from evidence is critical in this space, which is flooded with unsubstantiated claims.
Relevant Peptides
Russian telomere research; limited independent validation.
503A listed; genomic age-reversal data; actual clinical trials.
Mitochondrial; exercise mimetic in aged animals; no human trials.
Centenarian association; neuroprotection in animal models.
Phase II cardiac trials; mitochondrial protection with clinical data.
Senolytic; impressive mouse data; no human data.
Anti-aging protein; primate cognitive data.
25-year Russian observational data; not independently replicated.
Russian; thymic anti-aging claims.
Evidence-Based Anti-Aging Hierarchy
Most credible (actual clinical trials):
- GHK-Cu: Multiple peer-reviewed RCTs for skin; 503A compoundable
- SS-31: Phase II heart failure trials; mechanistically grounded
Promising but preclinical:
- MOTS-c, Humanin: Compelling animal/correlational data; no human trials
- Foxo4-DRI: Striking mouse data; no human trials
Speculative:
- Epithalon, Cortagen, Vilon, Pinealon: Russian observational data; not independently replicated
The Marketing Problem
Anti-aging is the segment most saturated with exaggerated claims. Compounds like Epithalon are marketed as “proven telomere elongators” based on a single Russian in vitro study. The actual human evidence for telomere elongation is non-existent.
Apply the highest skepticism to any anti-aging peptide marketing.
Stay current on peptide evidence
Weekly regulatory updates and study breakdowns. Free.